



Zelda Therapeutics Ltd
ACN 103 782 378
www.zeldatherapeutics.com
Level 45
108 St Georges Terrace,
Perth Western Australia 6000

12 October 2016

SUPPLEMENTARY PROSPECTUS

The Board of **Zelda Therapeutics Ltd (ASX: ZLD formerly Gleneagle Gold Ltd)** confirms that on 11 October 2016 it lodged a supplementary prospectus with the Australian Securities & Investment Commission which extends the offer period by a minimum of one month.

Unfortunately, due to technical issues associated with having the company re-admitted to ASX for quotations the company is required to issue the attached supplementary prospectus and extend the offer period until no earlier than the 11 November 2016.

The Company confirms that it has received valid subscriptions for \$4,000,000. This extension is merely a result of a technical issue related to having shares quoted on the Australian Securities Exchange within three months of the lodgement of the prospectus.

The Board remains excited by the future potential of the Company and looks forward to updating shareholders as it moves through this offer extension period and formally completing the acquisition of Zelda Therapeutics Pty Ltd. The company is confident of completing its ASX readmission requirements shortly after 11 November 2016.

Under the terms of the Supplementary Prospectus, the indicative timetable for the reinstatement of Zelda is now as follows:

Closing Date for the Offers	11 November 2016
Dispatch of holding statements	18 November 2016
Expected date for Shares to be reinstated to trading on ASX	25 November 2016

Should you have any questions regarding the Supplementary Prospectus or the above timetable please contact the Lead Manager to the offer:

CPS Capital Group Pty Ltd

Kelly Smith
Kelly.Smith@cpscapital.com.au

Jason Peterson
Jason.Peterson@cpscapital.com.au

Yours faithfully

N J Bassett
Company Secretary

Zelda Therapeutics Limited

(formerly Gleneagle Gold Limited)

ACN 103 782 378

Supplementary Prospectus

Important information

This is a supplementary prospectus (**Supplementary Prospectus**) intended to be read with the prospectus dated 11 July 2016 (**Prospectus**) issued by Zelda Therapeutics Limited (formerly Gleneagle Gold Limited) ACN 103 782 378 (**Company**).

This Supplementary Prospectus is dated 11 October 2016 and was lodged with ASIC on that date. Neither ASIC nor ASX take any responsibility as to the contents of this Supplementary Prospectus.

This Supplementary Prospectus should be read together with the Prospectus. Other than the changes set out in this Supplementary Prospectus, all other details in relation to the Prospectus remain unchanged. To the extent of any inconsistency between this Supplementary Prospectus and the Prospectus, the provisions of this Supplementary Prospectus will prevail. Unless otherwise indicated, terms defined and used in the Prospectus have the same meaning in this Supplementary Prospectus.

The Company has issued both a printed and electronic version of this Supplementary Prospectus and the Prospectus. Electronic versions of both may be accessed at www.gleneaglegold.net.au.

This Supplementary Prospectus and the Prospectus are important documents that should be read in their entirety. If you are in any doubt as to the contents of this Supplementary Prospectus or the Prospectus, you should consult your stockbroker, lawyer, accountant or other professional adviser without delay.

1. SUPPLEMENTARY PROSPECTUS

1.1 Reasons for this Supplementary Prospectus

This Supplementary Prospectus has been prepared to:

- (a) extend the period for admission to quotation of Shares offered under the Prospectus from three months from the date of the Prospectus to three months from the date of this Supplementary Prospectus (**Quotation Condition**); and
- (b) extend the period for the minimum subscription to the public offer under the Prospectus (**Minimum Subscription**) being achieved from the date four months after the date of the Prospectus to four months from the date of this Supplementary Prospectus (**Minimum Subscription Condition**),

pursuant to the ASIC Corporations (Minimum Subscription and Quotation Conditions) Instrument 2016/70 (**Instrument**).

1.2 Minimum Subscription Condition

The Company makes the following statements regarding the Minimum Subscription Condition as required by the Instrument.

- (a) As at the date of this Supplementary Prospectus \$4 million has been raised, representing applications for 160 million Shares under the Prospectus.
- (b) The Minimum Subscription Condition is being amended to extend the period for the Minimum Subscription being achieved from the date four months after the date of the Prospectus to four months from the date of this Supplementary Prospectus.
- (c) The Minimum Subscription Condition must be satisfied by 13 February 2017, being the first business day after the date that is four months from the date of this Supplementary Prospectus.

1.3 Quotation Condition

The Company makes the following statements regarding the Quotation Condition as required by the Instrument.

- (a) An application for admission to quotation of the Shares offered under the Prospectus was made within 7 days after the date of the Prospectus.
- (b) The Shares offered under the Prospectus have not been admitted to quotation as at the date of this Supplementary Prospectus.
- (c) ASX has not indicated that the Shares offered under the Prospectus will not be admitted to quotation.
- (d) The Quotation Condition is being amended to extend the period for admission to quotation of Shares offered under the Prospectus from three months from the date of the Prospectus to three months from the date of this Supplementary Prospectus.
- (e) The Quotation Condition must be satisfied by 11 January 2017, being the date three months from the date of this Supplementary Prospectus.
- (f) As at the date of this Supplementary Prospectus the number of Shares for which applications have been received is as specified in paragraph 1.2(a) above.

On 22 September 2016, the Company received a conditional reinstatement letter from ASX. As at the date of this Supplementary Prospectus, and assuming that applications received to date are not withdrawn, the Company has or is in a position to satisfy all of the conditions set out in the letter. The Company has issued this Supplementary Prospectus because it was not able to satisfy all of these conditions sufficiently before 11 October 2016 to allow the quotation of its Shares on or before that date.

2. APPLICATIONS

2.1 Investors who HAVE previously submitted an Application Form

A copy of this Supplementary Prospectus will be sent to all applicants who have subscribed for Shares under the Prospectus prior to the date of this Supplementary Prospectus. In accordance with section 724 of the Corporations Act, the Company will allow investors who have lodged Application Forms prior to the date of this Supplementary Prospectus 1 month from the date of this Supplementary Prospectus (being 11 November 2016) to obtain a refund of their Application Monies if they do not wish to proceed with their application (the **Withdrawal Period**). The Offers will remain open at least until the end of the Withdrawal Period.

Any investor who wishes to obtain a refund under the Public Offer should write to CPS Capital Group Pty Limited, Lead Manager, at the following address:

Zelda Therapeutics Limited
c/- CPS Capital Group Pty Limited
Level 45, 108 St Georges Terrace
PERTH WA 6000
Attention: Kelly.Smith@cpscapital.com.au

If you do not wish to withdraw your application, you do not need to take any action.

2.2 Investors who HAVE NOT previously submitted an Application Form and/or a Supplementary Application Form

The Offers of Shares are made in the Prospectus and this Supplementary Prospectus. If you wish to apply for Shares and have not yet completed an Application Form and/or a Supplementary Application Form, please complete and return the relevant Supplementary Application Form which is attached to this Supplementary Prospectus.

The relevant Supplementary Application Form must be received by 5.00pm (WST) on 11 November 2016 and must be completed in accordance with the relevant instructions in Section 1 of the Prospectus and the Supplementary Application Form. Applications must NOT be made on an Application Form attached to or accompanying the original Prospectus.

3. AMENDMENTS TO THE PROSPECTUS

3.1 Indicative timetable

The indicative timetable set out in the "Key Offer Details" and "Investment Overview" sections of the Prospectus is deleted and replaced with the following:

Indicative timetable	
Lodgement of the Prospectus with ASIC	11 July 2016
Opening Date for the Offers	12 July 2016
Closing Date for the Offers	11 November 2016
Dispatch of holding statements	18 November 2016
Expected date for Shares to be reinstated to trading on ASX	25 November 2016

3.2 Minimum Subscription

Paragraph 3.4 of Section 3 of the Prospectus is deleted and replaced with the following:

If the minimum subscription to the Public Offer of \$3,000,000 has not been raised by 10 February 2017, the Company will not issue any Securities and will repay all application monies for the Shares within the time prescribed under the Corporations Act, without interest.

3.3 ASX Listing

Paragraph 3.7 of section 3 of the Prospectus is deleted and replaced with the following:

If the Shares are not admitted to Official Quotation by ASX 11 January 2017, the Company will not issue any Shares and will repay all application monies for the Shares within the time prescribed under the Corporations Act, without interest.

The fact that ASX may grant Official Quotation to the Shares is not to be taken in any way as an indication of the merits of the Company or the Shares now offered for subscription.

4. DIRECTORS' AUTHORISATION

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Supplementary Prospectus with ASIC and has not withdrawn that consent prior to lodgement.

Signed for and on behalf of the Company on 11 October 2016.



Ian David Love
Director